Thromboembolic prevention in frail elderly patients with atrial fibrillation: A practical algorithm

Journal of the American Medical Directors Association

Volumn 16, Issue 5, 2015, Pages 358-364

  Granziera, Serena ^a,b   Cohen, Alexander T ^c   Nante, Giovanni ^a   Manzato, Enzo ^a   Sergi, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atrial fibrillation; Bleeding risk; Elderly; Frailty; Oral anticoagulants; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTIARRHYTHMIC AGENT;

ALGORITHM; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; DYSPHAGIA; FALL RISK ASSESSMENT; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMAN; INCIDENCE; LIFE EXPECTANCY; MEDICATION COMPLIANCE; MOBILIZATION; NUTRITIONAL STATUS; PATIENT MONITORING; PATIENT SAFETY; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; AGED; BRAIN ISCHEMIA; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); FEMALE; MALE; PRACTICE GUIDELINE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; FRAIL ELDERLY; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; THROMBOEMBOLISM;

EID: 84928706247     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2014.12.008     Document Type: Review

References (54)

1. Wilke T., Groth A., Mueller S., et al. Incidence and prevalence of atrial fibrillation: An analysis based on 8.3 million patients. Europace 2013, 15:486-493.
2. Saposnik G., Black S.E., Hakim A., et al. Age disparities in stroke quality of care and delivery of health services. Stroke 2009, 40:3328-3335.
3. Camm A.J., Kirchhof P., Lip G.Y.H., et al. European Heart Rhythm A, European Association for Cardio-Thoracic S.Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010, 12:1360-1420.
4. Hylek E.M., Evans-Molina C., Shea C., et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696.
5. Ogilvie I.M., Newton N., Welner S.A., et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010, 123:638-645 e4.
6. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
7. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22:983-988.
8. Wang T.J., Massaro J.M., Levy D., et al. Arisk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003, 290:1049-1056.
9. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
10. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007, 370:493-503.
11. Singer D.E., Chang Y., Fang M.C., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151:297-305.
12. Hart R.G., Pearce L.A., Aguilar M.I. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007, 147:590-592.
13. van Walraven C., Hart R.G., Connolly S., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: The atrial fibrillation investigators. Stroke 2009, 40:1410-1416.
14. Flaker G.C., Eikelboom J.W., Shestakovska O., et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: The apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012, 43:3291-3297.
15. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e531S-e575S.
16. Fang M.C., Go A.S., Hylek E.M., et al. Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study. JAm Geriatr Soc 2006, 54:1231-1236.
17. Fang M.C., Chang Y., Hylek E.M., et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752.
18. Marinigh R., Lip G.Y., Fiotti N., et al. Age as a risk factor for stroke in atrial fibrillation patients: Implications for thromboprophylaxis. JAm Coll Cardiol 2010, 56:827-837.
19. van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993, 153:1557-1562.
20. Torn M., Bollen W.L., van der Meer F.J., et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005, 165:1527-1532.
21. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2013, 369:2093-2104.
22. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
23. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
24. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
25. Sardar P., Chatterjee S., Chaudhari S., Lip G.Y. New oral anticoagulants in elderly adults: Evidence from a meta-analysis of randomized trials. JAm Geriatr Soc 2014, 62:857-864.
26. Tulner L.R., Van Campen J.P., Kuper I.M., et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: A prospective, descriptive study. Drugs Aging 2010, 27:39-50.
27. Parmelee P.A., Thuras P.D., Katz I.R., Lawton M.P. Validation of the cumulative illness rating scale in a geriatric residential population. JAm Geriatr Soc 1995, 43:130-137.
28. Gage B.F., Boechler M., Doggette A.L., et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000, 31:822-827.
29. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk. JAm Coll Cardiol 2011, 57:1339-1348.
30. Harel Z., Sholzberg M., Shah P.S., et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. JASN 2014, 25:431-442.
31. Kooiman J., van Rein N., Spaans B., et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PloS One 2014, 9:e94420.
32. Turpie A.G., Kreutz R., Llau J., et al. Management consensus guidance for the use of rivaroxaban-An oral, direct factor Xa inhibitor. Thromb Haemost 2012, 108:876-886.
33. Linjakumpu T., Hartikainen S., Klaukka T., et al. Use of medications and polypharmacy are increasing among the elderly. JClin Epidemiol 2002, 55:809-817.
34. Holbrook A., Schulman S., Witt D.M., et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e152S-e184S.
35. Froom P., Miron E., Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003, 120:526-528.
36. Barat I., Andreasen F., Damsgaard E.M. Drug therapy in the elderly: What doctors believe and patients actually do. Br J Clin Pharmacol 2001, 51:615-622.
37. Doggrell S.A. Adherence to medicines in the older-aged with chronic conditions: Does intervention by an allied health professional help?. Drugs Aging 2010, 27:239-254.
38. Cohen A.T., Maillardet L., Yavin Y. Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. Thromb Haemost 2009, 101:422-427.
39. Waterman A.D., Milligan P.E., Bayer L., et al. Effect of warfarin nonadherence on control of the International Normalized Ratio. AJHP 2004, 61:1258-1264.
40. Pengo V., Crippa L., Falanga A., et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011, 106:868-876.
41. Plassman B.L., Langa K.M., Fisher G.G., et al. Prevalence of dementia in the United States: The aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
42. Pfeiffer E. Ashort portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. JAm Geriatr Soc 1975, 23:433-441.
43. Kagansky N., Knobler H., Rimon E., et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004, 164:2044-2050.
44. Khreizat H.S., Whittaker P., Curtis K.D., et al. The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy. Drugs Aging 2012, 29:307-317.
45. van Deelen B.A., van den Bemt P.M., Egberts T.C., et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005, 22:353-360.
46. Katz S., Ford A.B., Moskowitz R.W., et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963, 185:914-919.
47. Lawton M.P., Brody E.M. Assessment of older people: Self-maintaining and instrumental activities of daily living. The Gerontologist 1969, 9:179-186.
48. Fried L.P., Ferrucci L., Darer J., et al. Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care. JGerontol Ser A 2004, 59:255-263.
49. Guigoz Y., Vellas B., Garry P.J. Assessing the nutritional status of the elderly: The Mini-Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996, 542:S59-S65.
50. Gage B.F., Birman-Deych E., Kerzner R., et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005, 118:612-617.
51. Man-Son-Hing M., Nichol G., Lau A., Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159:677-685.
52. Akl E.A., Rohilla S., Barba M., et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: A systematic review. Cancer 2008, 113:1685-1694.
53. Pilotto A., Ferrucci L., Franceschi M., et al. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res 2008, 11:151-161.
54. Bliss M.R., McLaren R., Exton-Smith A.N. Mattresses for preventing pressure sores in geriatric patients. Mon Bull Minist Health Publ Health Lab Serv 1966, 25:238-268.